Patents by Inventor Naser Uddin Hoti

Naser Uddin Hoti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treatment of cancer using tissue-specific oncolytic adenoviruses
    Patent number: 8859287
    Abstract: The present invention includes the use of a nucleic acid sequence encoding an shRNA to target RNA interference against a cellular factor where such use can enhance oncolytic adenovius replication. The nucleic acid sequence encoding an shRNA can be introduced into an oncolytic adenovius construct via a recombination event, and such nucleic acid sequence encoding an shRNA can reside in either the E1 region or Fiber region of the oncolytic adenovius construct. In particular, the oncolytic adenovius construct optionally include a prostate specific promoter or prostate specific enhancer for issue specific expression in prostate cancer cells. The oncolytic adenovius constructs of the invention provides utility for the treatment of cancers, in particular prostate cancer.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: October 14, 2014
    Assignee: The Johns Hopkins University
    Inventors: Ronald Rodriguez, Naser Uddin Hoti
  • Compositions and Methods for Treatment of Cancer Using Tissue-Specific Oncolytic Adenoviruses
    Publication number: 20120308521
    Abstract: The present invention includes the use of a nucleic acid sequence encoding an shRNA to target RNA interference against a cellular factor where such use can enhance oncolytic adenovius replication. The nucleic acid sequence encoding an shRNA can be introduced into an oncolytic adenovius construct via a recombination event, and such nucleic acid sequence encoding an shRNA can reside in either the E1 region or Fiber region of the oncolytic adenovius construct. In particular, the oncolytic adenovius construct optionally include a prostate specific promoter or prostate specific enhancer for issue specific expression in prostate cancer cells. The oncolytic adenovius constructs of the invention provides utility for the treatment of cancers, in particular prostate cancer.
    Type: Application
    Filed: December 2, 2010
    Publication date: December 6, 2012
    Inventors: Ronald Rodriguez, Naser Uddin Hoti